Arkolith/Insider Trading/PHIO/Form 4

Bitterman Robert J

Chairman, Pres. & CEO, DirectorPhio Pharmaceuticals Corp. (PHIO) · full profile →Form 4 · filed Jan 2, 2026
Net Buying
Open-Market Buys
$5K
Open-Market Sells
$0
Net Open-Market Flow
$5K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 31, 2025Buy(P)5K$1.03$5K291K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001683168-26-000013) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML